Enriched Renal Cell Assays for Toxicity Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug discovery processes face high attrition rates due to ineffective pre-clinical models and assay systems, leading to significant economic losses and risks to patient health, as many drug candidates fail to progress due to toxicity issues that could have been predicted earlier.
Innovation Solution
The development of methods using heterogeneous renal cell populations, specifically enriched with tubular cells and depleted of certain cell types, to screen test agents for renal toxicity and metabolism, involving culturing techniques such as 3D matrices and toxicity indicators like GGT expression and Aquaporin changes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional pre-clinical models and assay systems are used to evaluate drug candidates, then the drug development process can proceed through standard testing protocols, but high attrition rates occur due to unacceptable toxicity levels that are only identified after significant time and expense are invested
Solution Approach 1:
The patent segments the renal cell population into distinct functional subsets (tubular cells, glomerular cells, vascular cells, interstitial cells) and uses specific enriched populations (e.g., B2 tubular cell-enriched population) to isolate and evaluate specific toxicity mechanisms. This segmentation allows targeted assessment of nephrotoxicity pathways that are relevant to human renal function, improving prediction accuracy while reducing unnecessary testing of non-representative cell types.
Solution Approach 2:
The patent changes the key parameter of cell population composition by depleting non-representative cell types (e.g., B1 cell population) and enriching for human-relevant renal cell populations. This parameter change transforms the assay system from using generic or non-human renal cells to using depleted and enriched populations that better mimic human kidney physiology, thereby improving toxicity prediction reliability and enabling earlier identification of human-specific toxicities.
2Reliability
If comprehensive pre-clinical testing is conducted to evaluate all pharmacologic parameters, then complete safety and efficacy data are obtained, but significant expense is incurred before drug failure can be identified
Solution Approach 1:
The patent performs preliminary toxicity evaluation using depleted and enriched renal cell populations before advancing drug candidates to later, more expensive development stages. By using these specialized cell populations early in the process, the system identifies toxicities that would otherwise be detected only after substantial investment, thereby preventing waste of resources on non-viable candidates while maintaining comprehensive safety evaluation.
Solution Approach 2:
The patent extracts and removes non-representative cell populations (e.g., B1 cell population) from the renal cell mixture, retaining only the cell types that are relevant to human nephrotoxicity. This extraction process eliminates unnecessary testing components while preserving the essential toxicologic evaluation capabilities, reducing development expense without compromising the completeness of safety assessment.
3Ease of operation
If standard renal cell populations are used for toxicity screening, then the assay system is simple to implement, but it fails to accurately predict human in vivo responses due to presence of inactive or undesired cellular components
Solution Approach 1:
The patent segments the renal cell population to isolate specific functional cell types (tubular, glomerular, vascular, interstitial cells) and uses enriched populations that mimic human kidney composition. This segmentation improves measurement precision by ensuring that only relevant cell types contribute to toxicity signals, while the enrichment process maintains operational simplicity through standardized cell preparation protocols.
Solution Approach 2:
The patent changes the cell population composition parameter by depleting non-representative cells and enriching for human-relevant renal cells. This parameter change enhances toxicity prediction accuracy without significantly complicating the assay, as the depletion and enrichment processes can be integrated into existing cell culture workflows, maintaining ease of operation while improving measurement precision.
Data Source
Figure 1A~1B
Figure 2~3
Figure 4
AI summary
The present invention concerns bioactive renal cell populations, in particular a B2 cell population comprising an enriched population of tubular cells and wherein the renal cell population is depleted of a B1 cell population, renal cell constructs, and methods of screening tests agents using the bioactive renal cell populations.